Neil Came

Validation of a modified pre-lysis sample preparation technique for flow cytometric minimal residual disease assessment in multiple myeloma, chronic lymphocytic leukemia, and B-non Hodgkin lymphoma

Emma Bayly, Vuong Nguyen, Adrian Binek, Anna Piggin, Kylie Baldwin, David Westerman, Neil Came

Journal article  |  2020  |  CYTOMETRY PART B-CLINICAL CYTOMETRY

BACKGROUND: Minimal residual disease (MRD) assessment of hematopoietic neoplasia below 10-4 requires more leukocytes than is usual..

A synonymous GATA2 variant underlying familial myeloid malignancy with striking intrafamilial phenotypic variability

Lucy C Fox, Michelle Tan, Anna L Brown, Peer Arts, Ella Thompson, Georgina L Ryland, Jennifer Lickiss, Hamish S Scott, Nicola K Poplawski, Kerry Phillips, Neil A Came, Paul James, Stephen B Ting, David S Ritchie, Jeff Szer, Christopher N Hahn, Anthony Schwarer, Piers Blombery

Journal article  |  2020  |  BRITISH JOURNAL OF HAEMATOLOGY

Undetectable minimal residual disease should be the goal of venetoclax therapy in relapsed and refractory chronic lymphocytic leukaemia

Thomas Lew, Mary Ann Anderson, Victor Lin, Sasanka Handunnetti, Neil Came, David Westerman, Wall Meaghan, Constantine Tam, Andrew W Roberts, John F Seymour

Conference Proceedings  |  2020  |  LEUKEMIA & LYMPHOMA

Undetectable peripheral blood MRD should be the goal of venetoclax in CLL, but attainment plateaus after 24 months

Thomas E Lew, Mary Ann Anderson, Victor S Lin, Sasanka M Handunnetti, Neil A Came, Piers Blombery, David A Westerman, Meaghan Wall, Constantine S Tam, Andrew W Roberts, John F Seymour

Journal article  |  2020  |  BLOOD ADVANCES

The highly selective BCL2 inhibitor venetoclax achieves deep responses in patients with relapsed or refractory (R/R) chronic lymph..

AN UNDETECTABLE PB MRD STATUS SHOULD BE THE THERAPEUTIC GOAL WITH VENETOCLAX THERAPY IN RELAPSED/ REFRACTORY CLL

SM Handunnetti, TE Lew, VS Lin, MA Anderson, D Carney, M Wolf, N Came, S Juneja, D Westerman, CS Tam, AW Roberts, JF Seymour

Conference Proceedings  |  2019  |  Hematological Oncology

Reference ranges of peripheral blood lymphoid subsets by 10-colour flow cytometry based on 69 healthy adults from Australia

J Brotchie, P Chapple, N Came, D Liew, S Juneja

Journal article  |  2016  |  PATHOLOGY

Aggressive and extramedullary plasma cell myeloma evade bone marrow flow cytometric minimal residual disease detection

Neil Came, Nguyen Vuong, David Westerman, Simon Harrison

Journal article  |  2016  |  BRITISH JOURNAL OF HAEMATOLOGY

Consensus Guidelines on Plasma Cell Myeloma Minimal Residual Disease Analysis and Reporting

Maria Arroz, Neil Came, Pei Lin, Weina Chen, Constance Yuan, Anand Lagoo, Mariela Monreal, Ruth de Tute, Jo-Anne Vergilio, Andy C Rawstron, Bruno Paiva

Journal article  |  2016  |  CYTOMETRY PART B-CLINICAL CYTOMETRY

BACKGROUND: Major heterogeneity between laboratories in flow cytometry (FC) minimal residual disease (MRD) testing in multiple mye..

The denominator variable in the quantitation of MRD in acute myeloid leukemia

Neil Came, David Westerman, Surender Juneja

Journal article  |  2015  |  AMERICAN JOURNAL OF HEMATOLOGY

Plerixafor plus pegfilgrastim is a safe, effective mobilization regimen for poor or adequate mobilizers of hematopoietic stem and progenitor cells: a phase I clinical trial

KE Herbert, L Demosthenous, G Wiesner, E Link, DA Westerman, N Came, DS Ritchie, S Harrison, JF Seymour, HM Prince

Journal article  |  2014  |  BONE MARROW TRANSPLANTATION

The safety, kinetics and efficacy of plerixafor+pegfilgrastim for hematopoietic stem and progenitor cell (HSPC) mobilization are p..